Skip to main content

Advanced Search

Projected result for your current search:: 0

Search Operators:

You can use operators in your search query to narrow down your results even more. Click on the search operator to see an explanation of how it works.
Finds documents with exactly this word group, in exactly this word order and spelling (e.g. "employer branding").
Finds documents with both search terms (e.g. sales AND bonus).
Finds documents with one or the other search term (e.g. porsche OR volkswagen).
Finds documents with all search terms. Blank space is understood as AND (e.g. man robot production).
Finds documents with no appearance of the word behind NOT (e.g. ford NOT "harrison ford").
Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g. COUNT(gear)>8).
Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Finds documents with the search term in different spellings. "?" allows only one character (e.g. organi?ation).
Special characters are understood as AND (e.g. Miller Bros. & Sons).
 Log in
Top
Current Cardiology Reports

Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer

Published in:
Authors
Amit Manhas
Dipti Tripathi
Dilip Thomas
Nazish Sayed
Published in
Current Cardiology Reports | Issue 9/2024

Abstract

Purpose of Review

This review explores the cardiovascular toxicity associated with cancer therapies, emphasizing the significance of the growing field of cardio-oncology. It aims to elucidate the mechanisms of cardiotoxicity due to radiotherapy, chemotherapy, and targeted therapies, and to discuss the advancements in human induced pluripotent stem cell technology (hiPSC) for predictive disease modeling.

Recent Findings

Recent studies have identified several chemotherapeutic agents, including anthracyclines and kinase inhibitors, that significantly increase cardiovascular risks. Advances in hiPSC technology have enabled the differentiation of these cells into cardiovascular lineages, facilitating more accurate modeling of drug-induced cardiotoxicity. Moreover, integrating hiPSCs into clinical trials holds promise for personalized cardiotoxicity assessments, potentially enhancing patient-specific therapeutic strategies.

Summary

Cardio-oncology bridges oncology and cardiology to mitigate the cardiovascular side-effects of cancer treatments. Despite advancements in predictive models using hiPSCs, challenges persist in accurately replicating adult heart tissue and ensuring reproducibility. Ongoing research is essential for developing personalized therapies that balance effective cancer treatment with minimal cardiovascular harm.
Title
Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer
Authors
Amit Manhas
Dipti Tripathi
Dilip Thomas
Nazish Sayed
Publication date
23-07-2024
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 9/2024
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-024-02099-2
This content is only visible if you are logged in and have the appropriate permissions.

Other articles of this Issue 9/2024

Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?

  • Obesity
  • Public Health Policy (SS Virani and D Mahtta, Section Editors)

Molecular Regulation of Cardiac Conduction System Development

  • Pacemaker
  • Regenerative Medicine (SM Wu, Section Editor)

Obesity Paradox in Transcatheter Aortic Valve Replacement

  • Obesity
  • Valvular Heart Disease (TL Kiefer, Section Editor)

Latest recommendations for endocarditis in adult congenital heart disease

How to Optimize Goal-Directed Medical Therapy (GDMT) in Patients with Heart Failure

  • Open Access
  • Heart Failure
  • Heart Failure (HJ Eisen, Section Editor)

Can FDG-PET Imaging Identify Cardiac Sarcoidosis Disease Phenotypes?

  • Sarcoidosis
  • Nuclear Cardiology (V Dilsizian, Section Editor)

Next-generation MRI contrast agents: preparing the field (Link opens in a new window)

New MRI contrast agents are reshaping diagnostic imaging, promising lower gadolinium exposure amid evolving practice guidelines. How can you optimise contrast selection, dosing, and patient care in this rapidly advancing field?

This content is intended for healthcare professionals outside of the UK.

Independent Medical Education Grant:
  • Bayer HealthCare Pharmaceuticals Inc.
Learn more Link opens in a new window
Image Credits
Abstract graphic of layered, concentric circular shapes in bright green, pink, blue, and purple on a dark blue background. The rings and segments form a complex radial pattern without text/© Springer Health+ IME